Hanneke W M van Laarhoven (Hanneke Wm van Laarhoven)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 18

Top Topics

Locally Advanced

Squamous Cell Carcinoma

Prognostic Factors

Neoadjuvant Chemotherapy

Top Venues

Therapeutic advances in medical oncology

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Julie F M Geerts, Charlène J van der Zijden, Pieter C van der Sluis, Manon C W Spaander, Grard A P Nieuwenhuijzen, Camiel Rosman, Hanneke W M van Laarhoven, Rob H A Verhoeven, Bas P L Wijnhoven, Sjoerd M Lagarde, Bianca Mostert
Perioperative Chemotherapy for Gastro-Esophageal or Gastric Cancer: Anthracyclin Triplets versus FLOT. Cancers 16 (7) (2024)
Julie F M Geerts, Charlène J van der Zijden, Pieter C van der Sluis, Manon C W Spaander, Grard A P Nieuwenhuijzen, Camiel Rosman, Hanneke W M van Laarhoven, Rob H A Verhoeven, Bas P L Wijnhoven, Sjoerd M Lagarde, Bianca Mostert
Perioperative Chemotherapy for Gastro-Esophageal or Gastric Cancer: Anthracyclin Triplets versus FLOT. Cancers 16 (7) (2024)
Julie F M Geerts, Charlène J van der Zijden, Pieter C van der Sluis, Manon C W Spaander, Grard A P Nieuwenhuijzen, Camiel Rosman, Hanneke W M van Laarhoven, Rob H A Verhoeven, Bas P L Wijnhoven, Sjoerd M Lagarde, Bianca Mostert
Perioperative Chemotherapy for Gastro-Esophageal or Gastric Cancer: Anthracyclin Triplets versus FLOT. Cancers 16 (7) (2024)
Marieke Pape, Pauline A J Vissers, Willemieke P M Dijksterhuis, David Bertwistle, Laura McDonald, Bianca Mostert, Sarah Derks, Irma M Oving, Rob H A Verhoeven, Hanneke W M van Laarhoven
Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study. Therapeutic advances in medical oncology 15 (2023)
Irit Ben-Aharon, Hanneke W M van Laarhoven, Elisa Fontana, Radka Obermannova, Magnus Nilsson, Florian Lordick
Early-Onset Cancer in the Gastrointestinal Tract Is on the Rise-Evidence and Implications. Cancer discovery (2023)
Simone Augustinus, Hanneke W M van Laarhoven, Geert A Cirkel, Jan Willem B de Groot, Bas Groot Koerkamp, Teresa Macarulla, Davide Melisi, Eileen M O'Reilly, Hjalmar C van Santvoort, Tara M Mackay, Marc G Besselink, Johanna W Wilmink, null null
Timing of Initiation of Palliative Chemotherapy in Asymptomatic Patients with Metastatic Pancreatic Cancer: An International Expert Survey and Case-Vignette Study. Cancers 15 (23) (2023)
Naomi Cornelia Anna van der Velden, Paul K J Han, Hanneke W M van Laarhoven, Filip Yves Francine De Vos, Lizza E L Hendriks, Sjaak A Burgers, Anne-Marie C Dingemans, Jan Maarten W van Haarst, Joyce Dits, Ellen M A Smets, Inge Henselmans
Prevalence and Predictors of Physician-Patient Discordance in Prognostic Perceptions in Advanced Cancer. The oncologist (2023)
Irit Ben-Aharon, Hanneke W M van Laarhoven, Elisa Fontana, Radka Obermannova, Magnus Nilsson, Florian Lordick
Early-Onset Cancer in the Gastrointestinal Tract Is on the Rise-Evidence and Implications. Cancer discovery 13 (3) (2023)
Angelica Petrillo, Elizabeth C Smyth, Hanneke W M van Laarhoven
Emerging targets in gastroesophageal adenocarcinoma: what the future looks like. Therapeutic advances in medical oncology 15 (2023)
Joachim Kikomeko, Tim Schutte, Merel J M van Velzen, Rianne Seefat, Hanneke W M van Laarhoven
Short-term fasting and fasting mimicking diets combined with chemotherapy: a narrative review. Therapeutic advances in medical oncology 15 (2023)
Marieke Pape, Pauline A J Vissers, Willemieke P M Dijksterhuis, David Bertwistle, Laura McDonald, Bianca Mostert, Sarah Derks, Irma M Oving, Rob H A Verhoeven, Hanneke W M van Laarhoven
Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study. Therapeutic advances in medical oncology 15 (2023)
Angelica Petrillo, Elizabeth C Smyth, Hanneke W M van Laarhoven
Emerging targets in gastroesophageal adenocarcinoma: what the future looks like. Therapeutic advances in medical oncology 15 (2023)
Joachim Kikomeko, Tim Schutte, Merel J M van Velzen, Rianne Seefat, Hanneke W M van Laarhoven
Short-term fasting and fasting mimicking diets combined with chemotherapy: a narrative review. Therapeutic advances in medical oncology 15 (2023)
Charlotte I Stroes, Sandor Schokker, Mohammed Khurshed, Stephanie O van der Woude, Ron Aa Mathôt, Marije Slingerland, Judith de Vos-Geelen, Massimo Zucchetti, Cristina Matteo, Erik van Dijk, Bauke Ylstra, Victor Thijssen, Sarah Derks, Tesfay Godefa, Willemieke Dijksterhuis, Gerben E Breimer, Otto M van Delden, Rob Ha Verhoeven, Sybren L Meijer, Maarten F Bijlsma, Hanneke W M van Laarhoven
A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT). Therapeutic advances in medical oncology 14 (2022)
Sarah Derks, Hanneke W M van Laarhoven
Can we do without chemotherapy? A perspective on the combinations nivolumab-chemotherapy and nivolumab-ipilimumab in metastatic gastric and esophageal cancer. Therapeutic advances in medical oncology 14 (2022)
Sarah Derks, Hanneke W M van Laarhoven
Can we do without chemotherapy? A perspective on the combinations nivolumab-chemotherapy and nivolumab-ipilimumab in metastatic gastric and esophageal cancer. Therapeutic advances in medical oncology 14 (2022)
Lenka N C Boyd, Mahsoem Ali, Laura Kam, Jisce R Puik, Stephanie M Fraga Rodrigues, Eline S Zwart, Freek Daams, Barbara M Zonderhuis, Laura L Meijer, Tessa Y S Le Large, Elisa Giovannetti, Hanneke W M van Laarhoven, Geert Kazemier
The Diagnostic Value of the CA19-9 and Bilirubin Ratio in Patients with Pancreatic Cancer, Distal Bile Duct Cancer and Benign Periampullary Diseases, a Novel Approach. Cancers 14 (2) (2022)
Astrid E Slagter, Irene A Caspers, Nicole C T van Grieken, Iris Walraven, Pehr Lind, Elma Meershoek-Klein Kranenbarg, Cecile Grootscholten, Marianne Nordsmark, Johanna W van Sandick, Karolina Sikorska, Cornelis J H van de Velde, Edwin P M Jansen, Marcel Verheij, Hanneke W M van Laarhoven, Annemieke Cats
Triplet Chemotherapy with Cisplatin versus Oxaliplatin in the CRITICS Trial: Treatment Compliance, Toxicity, Outcomes and Quality of Life in Patients with Resectable Gastric Cancer. Cancers 14 (12) (2022)